Peter Whitfeld
Corporate Officer/Principal chez G2 Therapies Pty Ltd.
Profil
Peter Whitfeld is currently the Secretary & General Manager at G2 Therapies Pty Ltd.
He previously worked as a Principal at Novozymes Biopharma AU Ltd., Biotech Australia, The Fox Chase Cancer Center, and CSIRO's ICT Sector Advisory Council.
He also worked as a Professor at The Garvan Institute of Medical Research.
Dr. Whitfeld obtained a doctorate degree from the Australian National University.
Postes actifs de Peter Whitfeld
| Sociétés | Poste | Début |
|---|---|---|
G2 Therapies Pty Ltd.
 G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | Corporate Officer/Principal | 29/10/2010 |
Anciens postes connus de Peter Whitfeld
| Sociétés | Poste | Fin |
|---|---|---|
Biotech Australia
 Biotech Australia Pharmaceuticals: MajorHealth Technology Part of GroPrep Ltd., Biotech Australia develops medicines and technologies used for targeting specific diseases. Biotech Australia was acquired by GroPrep Ltd. on February 27, 2002. | Corporate Officer/Principal | - |
Novozymes Biopharma AU Ltd.
 Novozymes Biopharma AU Ltd. Pharmaceuticals: MajorHealth Technology Novozymes Biopharma AU Ltd. manufactures pharmaceuticals. The company is headquartered in Thebarton, Australia. | Corporate Officer/Principal | - |
The Fox Chase Cancer Center
 The Fox Chase Cancer Center Hospital/Nursing ManagementHealth Services The Fox Chase Cancer Center owns and operates hospitals. It is an independent, non-profit institution that is engaged in cancer treatment, research and prevention services. The firm's staff provides consultations and treatment recommendations for different types of adult cancer. The company was founded in 1904 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
The Garvan Institute of Medical Research
 The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Corporate Officer/Principal | - |
| CSIRO's ICT Sector Advisory Council | Corporate Officer/Principal | - |
Formation de Peter Whitfeld
| Australian National University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Novozymes Biopharma AU Ltd.
Novozymes Biopharma AU Ltd. Pharmaceuticals: MajorHealth Technology Novozymes Biopharma AU Ltd. manufactures pharmaceuticals. The company is headquartered in Thebarton, Australia. | Health Technology |
Biotech Australia
Biotech Australia Pharmaceuticals: MajorHealth Technology Part of GroPrep Ltd., Biotech Australia develops medicines and technologies used for targeting specific diseases. Biotech Australia was acquired by GroPrep Ltd. on February 27, 2002. | Health Technology |
The Fox Chase Cancer Center
The Fox Chase Cancer Center Hospital/Nursing ManagementHealth Services The Fox Chase Cancer Center owns and operates hospitals. It is an independent, non-profit institution that is engaged in cancer treatment, research and prevention services. The firm's staff provides consultations and treatment recommendations for different types of adult cancer. The company was founded in 1904 and is headquartered in Philadelphia, PA. | Health Services |
G2 Therapies Pty Ltd.
G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | Health Technology |
| CSIRO's ICT Sector Advisory Council | |
The Garvan Institute of Medical Research
The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Commercial Services |
